

Supplementary Table 1: Changes in lymphocyte subpopulations in peripheral blood of healthy donors (HD) vs omalizumab patients (OZB) and non-immunomodulatory drugs patients (NID)

Subpopulations	Parent	Percentage (%) Healthy donors		Percentage (%) Omalizumab		Percentage (%) NID		HD VS NID (p)	HD Vs OZB (p)	NID VS OZB (p)
CD4⁺ T lymphocytes	T cells	62.28	[44.4-83.9]	47.9	[32.9-63]	42.7	[25.1-69.9]	<0.0001	<0.001	0.38
CD4 T naïve	T CD4	40.9	[15.7-74.9]	43.4	[22.1-72.3]	58.9	[23.6-74.9]	<0.0001	>0.99	0.0025
CD4 T central memory	T CD4	39.3	[26.1-58.2]	36.3	[19.5-62.9]	29.1	[13.4-61.5]	<0.0001	0.7	0.002
CD4 T effector memory	T CD4	15.5	[2.3-32]	15.9	[5.7-28.1]	10.3	[6.6-40.4]	0.06	>0.99	0.01
CD4 T EMRA	T CD4	3.7	[0.1-28.8]	2	[0.2-8.8]	1.2	[0.5-18.9]	0.66	>0.99	0.18
CD4 T DR+CD38+	T CD4	1.4	[0.65-2.19]	1.05	[0.3-1.8]	0.8	[0.4-1.5]	<0.001	0.09	0.05
CD4 T DR+CD38-	T CD4	3.9	[0.9-12.10]	1.7	[0.5-16.2]	1.1	[0.6-3.5]	<0.001	0.0004	0.07
CD4 T DR-CD38+	T CD4	37.2	[18.4-52.0]	47.06	[15.6-66.6]	52.3	[21.7-71.4]	<0.001	>0.99	0.0013
Th1 CM	T CD4 CM	8.6	[5.10-14.30]	12.2	[4.3-24.9]	8.2	[3.9-27.5]	0.0047	>0.99	0.0036
Th1 EM	T CD4 EM	6.6	[1.6-17.90]	6.4	[2.5-16.4]	4.2	[2.5-19.8]	0.7	0.1	0.004
Th2 CM	T CD4 CM	7.2	[2.6-13.8]	8.2	[3.7-14.9]	6.4	[3.1-15.0]	>0.99	0.05	0.016
Th2 EM	T CD4 EM	1.5	[0.13-10.8]	2.1	[0.6-7.4]	2.1	[0.5-20.5]	0.08	0.004	0.2
CD8⁺ T lymphocytes	T cells	31.3	[12.7-48.5]	23.6	[16.4-40.4]	23.5	[13.2-35.4]	<0.0001	0.0005	0.09
CD8 T naïve	T CD8	39.8	[14.6-69.4]	23.3	[6.5-48.2]	35.3	[9.2-69.7]	0.54	0.0006	0.05
CD8 T central memory	T CD8	11.8	[0.1-33.8]	15.6	[5.6-42.2]	11.7	[1.4-29.1]	>0.99	0.13	0.09
CD8 T effector memory	T CD8	18.4	[0.4-37.1]	14.5	[7-26.9]	17.5	[0.6-49.2]	0.7	0.17	0.55
CD8 T EMRA	T CD8	30.7	[3.5-66.5]	46.5	[14.6-73.1]	35.3	[8.5-77.6]	0.62	0.0018	0.04
CD8 T DR+CD38+	T CD8	2.4	[0.61-4.46]	3	[0.3-7]	3.07	[0.1-9.3]	0.56	0.22	0.8
CD8 T DR+CD38-	T CD8	4.9	[0.7-16.6]	6.3	[0.3-38.9]	5.4	[0.5-24.4]	>0.99	>0.99	0.7
CD8 T DR-CD38+	T CD8	7.8	[1.92-14.2]	18.3	[3-37.3]	21.3	[3-36.9]	<0.0001	0.0005	0.7